About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 104315, 10 pages
http://dx.doi.org/10.1155/2013/104315
Review Article

Update on Anticytokine Treatment for Asthma

1Clinical Pharmacology Unit, Department of Health Science, University “Magna Græcia” of Catanzaro, Campus Universitario “S. Venuta”, Viale Europa-Località Germaneto, 88100 Catanzaro, Italy
2Department of Medical and Surgical Sciences, University “Magna Græcia” of Catanzaro, Campus Universitario “S. Venuta”, Viale Europa-Località Germaneto, 88100 Catanzaro, Italy
3Department of Respiratory Medicine, University of Salerno, 84084 Fisciano (SA), Italy

Received 29 April 2013; Accepted 7 June 2013

Academic Editor: Alexandre Paula Rogerio

Copyright © 2013 Luca Gallelli et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Current advances in the knowledge of asthma pathobiology suggest that anticytokine therapies can be potentially useful for the treatment of this complex and heterogeneous airway disease. Recent evidence is accumulating in support of the efficacy of anti-IL-4, anti-IL-5, and anti-IL-13 drugs. Therefore, these new developments are now changing the global scenario of antiasthma therapies, especially with regard to more severe disease. Current findings referring to variability of individual therapeutic responses highlight that the different asthma subtypes need to be well characterized, in order to implement phenotype-targeted treatments which in the near future will hopefully be mainly based on cytokine-directed biologics.